Skip to main content

Table 1 Definition of the clinical endpoints for the 498 SEQC NB samples and the 175 AML samples

From: An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era

Endpoint category Data set Total samples(n) Endpoint Training set Validation set
Samples(n) 1 0 Samples(n) 1 0
Binary (1/0) SEQC NB 498 A_EFS_All (event, yes/no) 249 89 160 249 94 155
B_OS_All (death, yes/no) 249 51 198 249 54 195
C_SEX_All (female/male) 249 103 146 249 108 141
272 D_FAV_All (unfavorable/favorable) 136 45 91 136 46 90
176 E_EFS_HR (event, yes/no) 86 55 31 90 65 25
F_OS_HR (death, yes/no) 86 43 43 90 49 41
AML 175 Sex (female/male) 89 43 46 86 39 47
Cytogenetic risk (poor/good) 89 72 17 86 70 16
Continuous (time) SEQC NB 498 A_EFS_All (event, days) 249 249
B_OS_All (death, days) 249 249
176 E_EFS_HR (event, days) 86 90
F_OS_HR (death, days) 86 90
AML 175 EFS (event, months) 89 86
OS (death, months) 89 86
  1. EFS: Event-free survival; FAV: Unfavorable/Favorable (class label for extreme disease course); HR: High-risk patients; OS: Overall survival.